There are many types of mutations in patients with non-small cell lung cancer (nsclc), and egfr exon 20 insertion mutations (egfr ex20in) belong to a different category, this type of mutation is relatively rare, and overall, egfr ex20in accounts for 2% to 3% of non-small cell lung cancer. At a time when non-small cell lung cancer egfr inhibitors are emerging, patients with egfr ex20in are not sensitive to existing targeted drugs, and targeted therapy is still in a blank stage.
01 The objective response rate is 36%, and jnj-6372 brings new hope to lung cancer patients
At the just-concluded 2020 European Society oncology Virtual Conference (EMSO2020), amivantamab (jnj-61186372; jnj-6372) and the combination of lazirtib (razetinib) bring stunning data.
The first phase of the Chrysalis study showed that the median follow-up of patients treated for the first time for 7 months had a clinical benefit rate (CBR) of 100%, including 20 partial responses (PR).
At a median follow-up of oscitinib-resistant, unconotherapy patients for 4 months, the objective response rate orr was 36%, including 1 case (cr) and 15 cases of partial response (pr), of which 1 case of pr is pending. The clinical benefit rate (CBR) was 60%.
According to the researchers, amivantamab is a bispecific antibody that targets egfr and met, demonstrating its clinical activity in patients with primary and acquired egfr resistance mutations. On March 10, 2020, the FDA awarded amivantamab the title of Breakthrough Therapy for the treatment of patients with exon 20 insertion mutations and disease progression following platinum chemotherapy.
The study also showed that in the untreated cohort, the median duration of treatment was 7 months, and all patients showed a deep response regardless of the egfr genotype.
This study provides strong evidence for the effectiveness of amivantamab in treating patients with egfr ex20in mutations.
Dr. Byoung Chul Cho, Principal Professor of the Department of Medical Oncology at Yonsei Cancer Center Affiliated to Yonsei University School of Medicine, said: "Amivantamab containing razetinib is effective for advanced EGFR mutations NSCLC and can be used safely in combination. ”
Based on the safety and efficacy data reported here, new studies by amivantamab and razetinib have begun in the Phase 3 Mariposa and Phase 2 Chrysalis-2 studies.
02 Later, the country independently developed new drugs, and the disease control rate reached 100%
In view of the current situation that the treatment effect of egfr ex20in patients is not good, domestic pharmaceutical companies have also been working hard to carry out research and development of new drugs.
In 2019, the new drug jmt-101 independently developed in China and specifically for patients with egfr ex20in has been approved for clinical trials. The Phase I trial mainly tested the safety and tolerability of JMT-101, and observed the efficacy and pharmacokinetics.
The trial received a total of 23 patients with assessable efficacy, all of whom had received advanced colorectal cancer who had received acc and had not received systematic egfr-targeted therapy. Of these, 16 patients received JMT-101 monotherapy and 7 patients received jmt-101 combined with mfolfox6 or folfiri regimens.
The results showed that the objective response rate and disease control rate of 56.2% in patients receiving JMT-101 monotherapy were 12.5%, and the disease control rate was 57.1% in patients receiving combination therapy, and the disease control rate reached 100%, and the disease control time exceeded 24 weeks.
In terms of adverse reactions, dose limit toxicity was not observed, the maximum tolerated dose was not reached, and no serious adverse reactions associated with treatment were observed. The most common adverse events included rash (81.3% in the monotherapy group and 100% in the combined group), proteinuria (62.5% in the monotherapy group and 28.6% in the combined group), and oral mucosal ulceration (86.0% in the combined group).
At present, the follow-up clinical trials of the drug have been carried out in major hospitals in China, patient recruitment is underway, and patients with relevant indications can communicate with experts to assess clinical benefits. (International Cell Clinical and Research)
So far, thousands of drugs have been discovered and developed, and with the help of medicines, we have been able to overcome disease and prolong life. Researchers obtain newer and better treatments through clinical trials. Patients can receive new therapies that are not marketed in advance. Patients treated with new drugs are likely to achieve cures, prolong survival or alleviate suffering in clinical trials, which is undoubtedly a new hope for cancer patients who do not respond to existing treatments. Patients in need can register directly at the end of the article "Learn More"!